List of Small Molecule Pharmaceuticals Companies in Austria - 15

Previously known as AOP Orphan, AOP Health is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families as well as also the doctors and care professionals treating them. Needs. Science. Trust. The international healthcare group focuses on research, development and global sales of innovative treatment solutions. AOP Health believes it has a responsibility to make innovative integrated therapies and disease-management solutions available long term to as many patients as possible who suffer from rare diseases or require critical care.

APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies.A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for Covid-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus.

Austrianni GmbH is a pharmaceutical company with the mission to develop therapeutics for the prevention and treatment of tuberculosis.

Austrianova encapsulates living cells in tiny cellulose beads. The beads act as a microenvironment for living cells, allowing them to be metabolically active and divide, whilst being protected from the environment both in vivo (immunoprotection) and in vitro (sheer force, freezing stress protection). Cell-in-a-Box® enables allogenic or xenogenic mammalian cells to be protected from rejection by the immune system, but their porous nature allows therapeutic bioproducts to be released and encapsulated cells to survive for long periods. Cell-in-a-Box® has many advantages e.g. 1) clinically proven safety and efficacy upon implantation of encapsulated cells in patients 2) cells can grow within the capsules in bioreactors and are thus protected from shear forces - especially useful for fragile cells such as stem cells 3) freezing and storage of encapsulated mammalian cells at -80C for more than 5 years and then revival with greater than 90% viability, thus cells can be easily transported on dry ice. Bac-in-a-Box® enables probiotic bacteria and yeast to be encapsulated to protect them from harsh environments. Bac-in-a-Box® has a number of advantages e.g. 1) it is based on a natural polymer which is digestible 2) it totally protects probiotics from low pH as found in the stomach for extended periods (hours), allowing almost 100% of ingested probiotic cells to reach and be released in the lower intestine 3) it allows freeze drying of probiotics without appreciable loss of viability so they can be easily stored and transported at room temperature. We offer cell encapsulation R&D and cGMP production for both - mammalian cells (stem cells, engineered cell lines etc) all the way from the lab to clinical trial material (Cell-in-a-Box®) and for - bacteria and yeast encapsulation for excellent long term storage at ambient temperatures as well as 5 to 7 logs better protection from acid degradation in the stomach and later release in the large intestine (Bac-in-a-Box®).

We develop technologies for site-specific drug delivery to the Central Nervous System, in particular the brain, for effective care of high-need patients.

Medical Devices, Small Molecules

Innophore is a biotechnology company based in Graz, Austria, founded in 2017. It specializes in drug and enzyme discovery, primarily serving the biotech and pharmaceutical industries. As a spin-off of acib GmbH and the University of Graz, Innophore is supported by strategic investor EOSS Industries GmbH. The company focuses on developing high-value industrial and therapeutic enzymes, as well as environmentally friendly chemical production processes. Innophore employs an AI-guided platform that utilizes advanced 3D point-cloud technology to analyze protein structures, enhancing the identification and optimization of protein candidates. Its Catalophore platform improves traditional methods, enabling more effective drug repurposing and side-effect prediction. With access to high-performance supercomputing resources, Innophore can analyze extensive protein structure databases, accelerating research and development in the biotech sector. The company collaborates with a diverse team of experts and has established partnerships with leading global companies, including Merck and Henkel.

invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the biotechnology value chain, with in-house expertise in R&D, clinical development, CMC, IP, scouting and more. All of our approaches are designed with a single goal: To transform patients' lives, so that cancer doesn’t.

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota-carrageenan. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI).

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta (lefamulin), recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA. Nabriva is a commercial-stage biopharmaceutical company with locations in the United States (King of Prussia, PA, San Diego, CA), Austria (Vienna), and Ireland (Dublin), home of our corporate headquarters.

QUANTRO Therapeutics (“QUANTRO”) is a research-based entity that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programs in cancer and other diseases. QUANTRO will assemble a highly innovative drug-discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates interfering with transcriptional regulators. The first focus will be on cancer-associated transcription factors, which so far have been unamenable to pharmacologic intervention. QUANTRO was founded as a spin-off of the Institute of Molecular Biotechnology (“IMBA”) and the Research Institute of Molecular Pathology (“IMP”), both located in Vienna, Austria.

Scantox is a preclinical GLP-accredited CRO, specialized in providing services within the drug development process Discovery, Genetic Toxicology, Regulatory Toxicology and Pharmaceutical Development & Analytical. Based on decades of experience, we are a trusted partner for CRO services for the pharmaceutical and medical devices industries. The Scantox Group is headquartered in Ejby, Denmark, with subsidiaries in UK, Austria, Denmark and Sweden (Lund and Gothenburg). The Scantox services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. The Scantox team is passionate about the common vision to improve the health of people, and all processes are rooted in dedication and guided by a strong sense of purpose. Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo. Certified as a 2023 Great Place To Work™. #pharmacology #toxicology #histopathology #pathology #minipigtoxicology #neuropharmacology #genotox

No idea what they do

VALANX Biotech is a biotechnology company based in Graz, Austria, founded in 2017 as a spin-off from Graz University of Technology. The company specializes in site-specific protein conjugation, focusing on advancing biologics development through synthetic biology and genetic code expansion. VALANX operates additional lab facilities at the Vienna Biocenter. The company offers a patented protein conjugation platform that allows precise control over conjugation sites and modifications on target proteins. This technology incorporates non-natural amino acids, enabling the development of protein-drug conjugates, diagnostics, and biocatalysis products. VALANX aims to create biologics for therapeutic and diagnostic applications, particularly in cancer drug targeting, with the capability of up to 10 selectable conjugation sites per protein. The company collaborates with partners to enhance reproducibility and cost efficiency in conjugate development and has raised $2.56 million in funding.

VelaLabs - founded 2006 - is a GLP and GMP-certified and G(C)LP compliant contract laboratory focusing on analytical and quality services of biopharmaceutical products supporting BIOTECH and PHARMA companies in the clinical development of biosimilars, biologics and ATMPs. By the acquisition of LABH in 2019 and building a clean room in 2020, VelaLabs also offers all types of microbiological services. Together with its strong team, the VelaLabs Management aims to successfully realize its vision of being a trusted partner for our customers along the process of medication development.